Many physicians prescribe more than one antiulcerative agent (AUA) simultaneously to the same patient, although there is little evidence to support this practice.
The purposes of this study were to (a) determine patient factors associated with the concurrent use of these agents and (b) estimate the excess costs generated by the prescription of multiple rather than a single agent.
We conducted a case-control study of concurrent AUA users among New Jersey Medicaid enrollees age 65 years and older.
To evaluate the excess cost generated by the ongoing prescription of an additional AUA, we measured the additional drug expenditures associated with each regimen of concurrent use.
Nearly 1 in 15 AUA users (6.6%) met our conservative definition of concurrent AUA use.
In a multiple logistic regression model, previous gastrointestinal procedure, use of a nonsteroidal anti-inflammatory drugs, nursing home residency, and recent hospitalization for more than 20 days were all predictors of concurrent use of more than one AUA.
No association was found with age, sex, or number of pharmacies used.
The upper bound estimate of the cost generated by the concurrent prescription of a second AUA was $210 (range : $2-$942) over the 180-day study period, with a lower bound of $151 (range : $1-$449).
Annually, such excess cost would range from $301 to $420 per patient. (...)
Mots-clés Pascal : Antiulcéreux, Epidémiologie, Incidence, Traitement associé, Relation médecin malade, Coût, Etude cas témoin, Evaluation, Homme, Critère âge, Chimiothérapie, Appareil digestif pathologie, Economie santé
Mots-clés Pascal anglais : Antiulcer agent, Epidemiology, Incidence, Combined treatment, Physician patient relation, Costs, Case control study, Evaluation, Human, Age criterion, Chemotherapy, Digestive diseases, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0407397
Code Inist : 002B02H. Création : 19/12/1997.